Zacks Investment Research upgraded shares of AnaptysBio, Inc. (NASDAQ:ANAB) from a hold rating to a buy rating in a report released on Tuesday morning. Zacks Investment Research currently has $24.00 target price on the biotechnology company’s stock.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
A number of other analysts also recently commented on the company. Stifel Nicolaus upped their target price on AnaptysBio from $30.00 to $35.00 and gave the stock a buy rating in a research note on Tuesday, May 2nd. Credit Suisse Group restated an outperform rating and issued a $34.00 target price on shares of AnaptysBio in a research note on Tuesday, April 18th. Finally, Robert W. Baird started coverage on AnaptysBio in a research note on Monday, July 10th. They issued an outperform rating and a $36.00 target price on the stock. Six analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and an average price target of $33.67.
AnaptysBio (NASDAQ:ANAB) opened at 22.06 on Tuesday. The company’s market cap is $448.74 million. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $30.71. The stock has a 50 day moving average price of $24.30 and a 200 day moving average price of $24.51.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.29. The company had revenue of $7 million during the quarter, compared to analysts’ expectations of $3.45 million. On average, equities research analysts anticipate that AnaptysBio will post ($1.96) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades AnaptysBio, Inc. (ANAB) to Buy” was first reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/zacks-investment-research-upgrades-anaptysbio-inc-anab-to-buy.html.
In related news, major shareholder Holdings A/S Novo sold 178,600 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $21.16, for a total value of $3,779,176.00. Following the completion of the transaction, the insider now owns 2,436,332 shares of the company’s stock, valued at approximately $51,552,785.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the company’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. Insiders sold a total of 777,640 shares of company stock valued at $16,705,386 in the last ninety days.
A number of institutional investors have recently added to or reduced their stakes in ANAB. Frazier Management LLC acquired a new position in AnaptysBio during the first quarter worth $102,354,000. Perceptive Advisors LLC acquired a new position in AnaptysBio during the first quarter worth $24,474,000. Hamilton Lane Advisors LLC acquired a new position in AnaptysBio during the first quarter worth $11,213,000. Marshall Wace North America L.P. acquired a new position in AnaptysBio during the first quarter worth $6,924,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in AnaptysBio during the first quarter worth $6,924,000. 71.56% of the stock is owned by institutional investors.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.